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Development of Hepatocellular Carcinoma after Achieving Sustained HCVVirologic Response and Regression of Cirrhosis
Harshita Mehrotra, MD., Beena Ahsan, MD., Mohammad Raoufi, MD
Department of Pathology (Anatomic & Clinical), Henry Ford Health System, Detroit, Michigan
Abstract
Introduction: Hepatocellular carcinoma (HCC) in a background of chronic
Hepatitis C virus (HCV) infection is an emerging cause of cancer mortality.
Interferon/ribavirin and direct acting antiviral (DAA) therapy have successfully
treated HCV infection and may halt the progression of fibrosis. It is generally
believed that achieving sustained viral response (SVR) could decrease the
incidence of HCC by slowing down fibrosing process; hence preventing
progression of cirrhosis.
Method:
Sixty-four-year-old female who was successfully treated for HCV infection with
interferon and achieved sustained viral response (SVR) with regular follow-up.
She presented with abdominal pain after more than 20 years. CT scan revealed a
liver mass which was subsequently biopsied and proven to be HCC. Patient was
treated with partial hepatectomy and histologic examination of the resected liver
mass revealed well-differentiated HCC; non-neoplastic liver demonstrated
features of regression of cirrhosis/fibrosis with fibrous expansion of few portal
tracts and scattered very fine curvilinear fibrous septa; no portal/lobular
inflammation was present.
Results:
The patient developed HCC more than 20 years after achieving SVR. Significant
regression of cirrhosis/fibrosis in the non-neoplastic liver argues against the
usual course of HCC development in cirrhotic/advanced fibrotic setting, and
suggests the possibility of an alternative phenomenon, e.g., latency of HCV
and/or oncologic potential of HCV at the genomic level.
Conclusion:
This rare event raises questions regarding relationship between regression of
cirrhosis/fibrosis and developing HCC which are currently under investigation.

Methods
• 64-year-old female initially presented with chronic hepatitis C
viral infection with progressive cirrhosis and fibrosis.
• She was successfully treated for HCV infection with interferon
in 1994 and achieved sustained viral response (SVR) with
regular follow-up.
• Twenty-three years after achieving SVR, she presented to the
gastroenterology clinic with abdominal pain in June 2017.
• Physical examination was unremarkable.
• CT scan revealed a 2 cm hyperattenuating liver mass which
was subsequently biopsied and proved to be well-differentiated
hepatocellular carcinoma (HCC).
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Background
• Hepatocellular carcinoma (HCC) is the third leading cause of
cancer-related deaths worldwide1.
• Patients with HCV-induced cirrhosis are at particularly high
risk for the development of HCC, with an annual incidence of
HCC ranging from 0.5% to 10%2.
• It is generally believed that HCC primarily occurs in the
background of HCV- related cirrhosis; theoretically, achieving
sustained viral response (SVR) could decrease the incidence of
HCC by slowing down fibrosing process; hence preventing
progression of cirrhosis.
• Interferon/ribavirin and direct acting antiviral (DAA) therapy
have successfully treated HCV infection and may halt the
progression of fibrosis.
• Sustained virologic response (SVR) with DAA has emerged as
the most dominant modifier of HCC in patients with HCV2.

Results
• Patient was treated with partial hepatectomy.
• Histologic examination of the resected liver mass revealed
well-differentiated HCC.
• Non-neoplastic liver demonstrated features of regression of
cirrhosis/fibrosis with fibrous expansion of few portal tracts
and scattered very fine curvilinear fibrous septa; no
portal/lobular inflammation was present.

Conclusions
• The patient developed HCC twenty-three years after achieving
SVR.
• Significant regression of cirrhosis/fibrosis in the nonneoplastic liver argues against the usual course of HCC
development in cirrhotic/advanced fibrotic setting, and
suggests the possibility of an alternative phenomenon, e.g.,
latency of HCV and/or oncologic potential of HCV at the
genomic level.
• This rare event raises certain questions which have not been
properly investigated in the course of HCC development, such
as:
o Relationship between regression of cirrhosis/fibrosis and
developing HCC;
o Does absence and regression of cirrhosis/fibrosis carry the
same value;
o Necessity of updating the surveillance criteria in patient
with SVR lacking cirrhosis; and
o Oncologic potential of HCV acquired at the genomic level;
these questions/issues are currently under investigation.
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Figure 1. H&E demonstrating well differentiated hepatocellular carcinoma.
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